Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.
about
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Subsequent NeoplasmsVariable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups.Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.The risk of secondary primary malignancies after therapy for multiple myeloma.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study.
P2860
Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Second primary malignancies af ...... antation for multiple myeloma.
@ast
Second primary malignancies af ...... antation for multiple myeloma.
@en
type
label
Second primary malignancies af ...... antation for multiple myeloma.
@ast
Second primary malignancies af ...... antation for multiple myeloma.
@en
prefLabel
Second primary malignancies af ...... antation for multiple myeloma.
@ast
Second primary malignancies af ...... antation for multiple myeloma.
@en
P2093
P2860
P1476
Second primary malignancies af ...... antation for multiple myeloma.
@en
P2093
Amrita Y Krishnan
Can-Lan Sun
Firoozeh Sahebi
George Somlo
Jennifer Berano Teh
Sandra H Thomas
Smita Bhatia
Stephen J Forman
Tongjun Kang
P2860
P304
P356
10.1016/J.BBMT.2012.09.023
P50
P577
2012-10-13T00:00:00Z